The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is continuing to evolve and grow beyond the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) and chemotherapy-based regimens. We anticipate label expansions of current therapies and the launch of four emerging therapies with diverse mechanisms of action during the 2022-2032 forecast period. These events will drive rapid growth in the SCCHN therapy market, increase the drug-treatable population, and revolutionize the treatment landscape, particularly for locoregionally advanced non-nasopharyngeal disease.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.